US Oncology Reports First Quarter 20...(( IGRT ) administered by network physici...),Health

First quarter cancer center services revenue increased $3.0 million, or 3.4 percent, and Adjusted EBITDA increased $1.2 million, or 4.0 percent from the fourth quarter of 2007 reflecting the contribution of results from newly affiliated practices and increased revenue associated with advanced radiation therapies.

Pharmaceutical Services

Pharmaceutical services revenue in the first quarter of 2008 was $610.6 million, an increase of $69.2 million, or 12.8 percent, over the first quarter of 2007. The revenue increase is primarily due to the net addition of 170 medical oncologists affiliated through comprehensive service and oncology pharmaceutical services ("OPS") agreements since the close of the first quarter of 2007. Since the first quarter of 2007, our network of affiliated medical oncologists has grown by 16 percent. The addition of physicians was partially offset by lower utilization of certain supportive care drugs due to coverage restrictions and safety concerns. Pharmaceutical services Adjusted EBITDA was $22.7 million for the first quarter of 2008, an increase of $0.3 million over the first quarter of 2007.

Pharmaceutical services revenue in the first quarter of 2008 increased $10.9 million, or 1.8 percent, and Adjusted EBITDA decreased $6.7 million from the preceding quarter. The revenue increase is due to the net addition of 48 affiliated medical oncologists during the quarter, as well as increased revenue from our oral oncology specialty pharmacy, OncologyRX CareAdvantage. The pharmaceutical services Adjusted EBITDA decrease of $6.7 million from the fourth quarter of 2007 is due to performance fees earned in the fourth quarter of 2007 that did not recur in the current quarter and lower utilization of supportive care drugs. Also, our OPS business faced margin pressures and increased credit risk during the first q
'/>"/>